Expert Opinion on Drug Safety, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 9
Published: July 15, 2024
Tirzepatide is a novel dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) for type 2 diabetes or obesity. To explore the safety profile of tirzepatide in real-world clinical applications.
Language: Английский
JAMA, Journal Year: 2024, Volume and Issue: 332(7), P. 571 - 571
Published: Aug. 20, 2024
Obesity affects approximately 19% of women and 14% men worldwide is associated with increased morbidity. Antiobesity medications (AOMs) modify biological processes that affect appetite significantly improve outcomes, such as type 2 diabetes, hypertension, dyslipidemia.
Language: Английский
Citations
48
Annals of Internal Medicine, Journal Year: 2024, Volume and Issue: 177(8), P. 1004 - 1015
Published: July 15, 2024
A major concern has recently emerged about a potential link between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and increased risk for suicidal ideation behaviors based on International Classification of Diseases codes.
Language: Английский
Citations
9
Diabetologia, Journal Year: 2024, Volume and Issue: 67(11), P. 2471 - 2480
Published: Aug. 5, 2024
Abstract Aims/hypothesis Regulators worldwide are reviewing safety data on glucagon-like peptide-1 receptor agonists (GLP-1RA), following reports by the Icelandic Medicines Agency in July 2023 of suicidal ideation and self-injury (SIS) individuals taking liraglutide semaglutide. We aimed to assess risk SIS new users GLP-1RA when compared with sodium-glucose cotransporter 2 inhibitors (SGLT-2i) users, prescribed treat type diabetes obesity. Methods This is a cohort study combining several population-wide databases covering Spanish population five million inhabitants, including all adults obesity who initiated treatment either or SGLT-2i for from 2015 2021. To estimate comparative effect SIS, we employed user, active comparator design carried out multivariable Cox regression modelling inverse probability weighting (IPTW) based propensity scores. performed stratified sensitivity analyses. Results included 3040 patients initiating 11,627 SGLT-2i. When treated SGLT-2i, those group were younger (55 vs 60 years old, p <0.001), had more anxiety (49.4% 41.5%, sleep disorders (43.2% 34.1%, <0.001) depression (24.4% 19.0%, obese (35.1% BMI ≥40 15.1%, <0.001). After score weighting, standardised mean differences between groups <0.1 covariates, showing adequate balance at baseline after adjustment. In main per-protocol analyses found no evidence that increased incidence (HR 1.04; 95% CI 0.35, 3.14). Intention-to-treat resulted an HR 1.36 (95% 0.51, 3.61). excluding information using imputation missing values, respective HRs 0.89 0.26, 3.14) 1.29 0.42, 3.92). Stratified showed subgroups. Conclusions/interpretation Our findings do not support obesity; however, rarity events wide uncertainty size (although null, may be compatible as high threefold) calls cautious interpretation our results. Further studies, final evaluations regulatory bodies, called discard causal link suicidality. Graphical
Language: Английский
Citations
9
Diabetes Obesity and Metabolism, Journal Year: 2024, Volume and Issue: 26(11), P. 5183 - 5191
Published: Aug. 19, 2024
To evaluate the potential association between suicidality and glucagon-like peptide-1 receptor agonists (GLP-1RAs), as well other medications used for obesity diabetes, using comprehensive global data.
Language: Английский
Citations
8
European Psychiatry, Journal Year: 2025, Volume and Issue: 68(1)
Published: Jan. 1, 2025
Abstract Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used due to their profound efficacy in glycemic control and weight management. Real-world observations have revealed potential neuropsychiatric adverse events (AEs) associated with GLP-1RAs. This study aimed comprehensively investigate characterize these AEs Methods We analyzed GLP-1RA reaction reports using the FDA Adverse Event Reporting System database. Disproportionality analysis reporting odds ratio (ROR) identified eight categories of conducted descriptive time-to-onset (TTO) analyses explored AE signals among individual GLP-1RAs for loss diabetes mellitus (DM) indications. Results 25,110 cases GLP-1RA-related AEs. showed an association headache (ROR 1.74, 95% confidence interval [CI] 1.65–1.84), migraine 1.28, 95%CI 1.06–1.55), olfactory sensory nerve abnormalities 2.44, 1.83–3.25; ROR 1.69, 1.54–1.85). Semaglutide a moderate suicide-related signal population 2.55, 1.97–3.31). The median TTO was 16 days (interquartile range: 3–66 days). Conclusions In this study, we and, first time, detected positive migraine, abnormalities, abnormalities. also observed semaglutide, population. provides reliable basis further investigation However, as exploratory our findings require confirmation through large-scale prospective studies.
Language: Английский
Citations
1
Nature Mental Health, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 13, 2025
Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are novel drugs approved for diabetes and obesity. They acknowledged as a major scientific breakthrough. In addition to their metabolic effects, these medications act on other bodily systems involved in the physiopathology of various neurological psychiatric disorders. Several stakeholders calling more research investigate repurposing potential GLP-1RAs cognitive mental disorders, while others advocate better assessment safety profile from neuropsychiatric perspective. this Analysis, we searched relevant literature effects across range illnesses, gathering describing available pre-clinical mechanistic (278 studies) clinical (96 evidence substance-use psychotic mood anxiety eating others. By leveraging translational insights data, consider implications practice propose avenues further research.
Language: Английский
Citations
1
European Neuropsychopharmacology, Journal Year: 2024, Volume and Issue: 87, P. 29 - 34
Published: July 27, 2024
Glucagon-like peptide-1 (GLP-1) agonists have been successfully used in clinical practice for the treatment of diabetes and obesity, offering significant benefits. However, concerns regarding their potential link to psychiatric side effects, like suicidal thoughts behaviours (STB) emerged. This narrative review investigates complex interplay between GLP-1 STB, focusing on biological stress induced by rapid weight loss, psychological social consequences, similar mechanism with addiction, evaluative lens Bradford Hill criteria causality. While can contribute substantial health improvements, they also introduce stressors. Disruptions homeostasis from quick reduction elevate cortisol norepinephrine levels, heightening risk for, or exacerbation STB. Psychological factors, including unfulfilled expectations identity changes after compound these risks. Utilizing reveals insufficient evidence a direct causal Yet, indirect effects related metabolic disturbances associated loss call cautious approach. Used carefully targeted populations may even emerge as protective agents against Therefore, it is crucial monitor patients during screen preexisting mental conditions. If detected, appropriate management should be applied. Future studies aim at optimizing dosing schedules mitigate adverse further investigate possible STB prevention.
Language: Английский
Citations
6
JAMA Network Open, Journal Year: 2024, Volume and Issue: 7(8), P. e2423335 - e2423335
Published: Aug. 20, 2024
Georgios Schoretsanitis, MD, PhD; Stefan Weiler, Corrado Barbui, MD; Emanuel Raschi, Chiara Gastaldon, PhD
Language: Английский
Citations
6
JAMA Pediatrics, Journal Year: 2024, Volume and Issue: unknown
Published: Oct. 14, 2024
Importance Glucagon-like peptide 1 receptor agonists (GLP1R) are increasingly being used for the treatment of obesity in adolescents. It is currently unknown whether GLP1R associated with suicidal ideation or attempts this population. Objective To investigate association between initiation and adolescents obesity. Design, Setting, Participants Retrospective propensity score–matched cohort study using electronic health records from TriNetX global federated network December 2019 June 2024. The analysis included data 120 care organizations, mainly USA. were aged 12 to 18 years a diagnosis evidence an antiobesity prescription lifestyle intervention without within following year. Cohorts balanced baseline demographic characteristics, psychiatric medications comorbidities, diagnoses socioeconomic status access score matching. Exposure Initial (study cohort) (control cohort). Main Outcomes Measures Incidence based on International Statistical Classification Diseases Related Health Problems, Tenth Revision codes recorded patient during months follow-up. Diagnoses upper respiratory tract infections (URTI) as negative control outcomes, gastrointestinal symptoms (GI) positive outcomes. Results A total 4052 concomitant identified 50 112 cohort. Propensity matching resulted 3456 participants each Prescription was 33% reduced risk over follow-up (1.45% vs 2.26%; hazard ratio [HR], 0.67; 95% CI, 0.47-0.95; P = .02) higher rate GI (6.9% 5.4%; HR, 1.41; 1.12-1.78; .003) but no difference rates URTI diagnoses. Conclusions Relevance In study, prescribed had lower incidence compared matched patients not who treated intervention. These results suggest favorable safety profile detected reduction HRs among suggests potential avenues future research.
Language: Английский
Citations
4
Current Obesity Reports, Journal Year: 2025, Volume and Issue: 14(1)
Published: Jan. 3, 2025
Language: Английский
Citations
0